drugset / Trial / NCT01813422

GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound

NCT01813422 ↗

Phase 3 Completed 970 enrolled Amgen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate whether low-density lipoprotein (LDL-C) lowering with evolocumab (AMG 145) results in greater change from baseline in percent atheroma volume (PAV) at week 78 than placebo in adults with coronary artery disease taking lipid lowering therapy.

Timeline

Start
2013-04-18
Primary completion
2016-07-12
Completion
2016-07-29

Outcome

Met primary endpoint

registry analysis (superiority or other test); Placebo vs Evolocumab; p < 0.0001; LS Mean Treatment Difference -1.007 (95% CI -1.375 to -0.640); ANCOVA NCT01813422 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Evolocumab Monoclonal antibody 420 mg Subcutaneous

Indications